The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...